{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:28:19Z","timestamp":1778574499014,"version":"3.51.4"},"reference-count":244,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2607,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds236","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:53:09Z","timestamp":1348620789000},"page":"2479-2516","source":"Crossref","is-referenced-by-count":1239,"title":["ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making"],"prefix":"10.1016","volume":"23","author":[{"given":"H.J.","family":"Schmoll","sequence":"first","affiliation":[]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[]},{"given":"A.","family":"Stein","sequence":"additional","affiliation":[]},{"given":"V.","family":"Valentini","sequence":"additional","affiliation":[]},{"given":"B.","family":"Glimelius","sequence":"additional","affiliation":[]},{"given":"K.","family":"Haustermans","sequence":"additional","affiliation":[]},{"given":"B.","family":"Nordlinger","sequence":"additional","affiliation":[]},{"given":"C.J.","family":"van de Velde","sequence":"additional","affiliation":[]},{"given":"J.","family":"Balmana","sequence":"additional","affiliation":[]},{"given":"J.","family":"Regula","sequence":"additional","affiliation":[]},{"given":"I.D.","family":"Nagtegaal","sequence":"additional","affiliation":[]},{"given":"R.G.","family":"Beets-Tan","sequence":"additional","affiliation":[]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[]},{"given":"P.","family":"Hoff","sequence":"additional","affiliation":[]},{"given":"D.","family":"Kerr","sequence":"additional","affiliation":[]},{"given":"C.H.","family":"K\u00f6hne","sequence":"additional","affiliation":[]},{"given":"R.","family":"Labianca","sequence":"additional","affiliation":[]},{"given":"T.","family":"Price","sequence":"additional","affiliation":[]},{"given":"W.","family":"Scheithauer","sequence":"additional","affiliation":[]},{"given":"A.","family":"Sobrero","sequence":"additional","affiliation":[]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[]},{"given":"D.","family":"Aderka","sequence":"additional","affiliation":[]},{"given":"S.","family":"Barroso","sequence":"additional","affiliation":[]},{"given":"G.","family":"Bodoky","sequence":"additional","affiliation":[]},{"given":"J.Y.","family":"Douillard","sequence":"additional","affiliation":[]},{"given":"H.","family":"El Ghazaly","sequence":"additional","affiliation":[]},{"given":"J.","family":"Gallardo","sequence":"additional","affiliation":[]},{"given":"A.","family":"Garin","sequence":"additional","affiliation":[]},{"given":"R.","family":"Glynne-Jones","sequence":"additional","affiliation":[]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[]},{"given":"A.","family":"Meshcheryakov","sequence":"additional","affiliation":[]},{"given":"D.","family":"Papamichail","sequence":"additional","affiliation":[]},{"given":"P.","family":"Pfeiffer","sequence":"additional","affiliation":[]},{"given":"I.","family":"Souglakos","sequence":"additional","affiliation":[]},{"given":"S.","family":"Turhal","sequence":"additional","affiliation":[]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds236_bb0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0015","article-title":"Global cancer statistics","volume":"61: 69\u201390","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mds236_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1093\/annonc\/mds236_bb0025","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdp530","article-title":"Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975","volume":"21","author":"La Vecchia","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/annonc\/mdq774","article-title":"European cancer mortality predictions for the year 2011","volume":"22","author":"Malvezzi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0040","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients","volume":"13","author":"Kohne","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0050","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0277-5379(91)90307-Y","article-title":"Determinants of prognosis in advanced colorectal cancer","volume":"27","author":"Graf","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0959-8049(94)90417-0","article-title":"Appraisal of a model for prediction of prognosis in advanced colorectal cancer","volume":"30A","author":"Graf","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0060","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0002-9343(83)91066-5","article-title":"Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count","volume":"74","author":"Kemeny","year":"1983","journal-title":"Am J Med"},{"key":"10.1093\/annonc\/mds236_bb0065","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T","article-title":"Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience","volume":"57","author":"Steinberg","year":"1986","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds236_bb0070","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0075","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/annonc\/mdm267","article-title":"Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification","volume":"18","author":"Sorbye","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC). Results of the translational study on the PETACC 3 - EORTC 40993 - SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.4002","article-title":"Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial","volume":"27","author":"Roth","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/djr153","article-title":"DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-Fluorouracil-based adjuvant therapy","volume":"103","author":"Sinicrope","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds236_bb0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","article-title":"Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer","volume":"29","author":"Hutchins","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0105","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2010.33.0092","article-title":"Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer\u2013a study of CALGB 9581 and 89803","volume":"29","author":"Bertagnolli","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jmedgenet-2011-100714","article-title":"Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification","volume":"49","author":"Parsons","year":"2012","journal-title":"J Med Genet"},{"key":"10.1093\/annonc\/mds236_bb0115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds236_bb0120","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.2010.28.9538","article-title":"Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II\/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin","volume":"28","author":"O'Connell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2010.30.1077","article-title":"Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer","volume":"29","author":"Salazar","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0130","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2010.32.8732","article-title":"Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer","volume":"29","author":"Gray","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","article-title":"Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"12","author":"Adams","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mds236_bb0140","doi-asserted-by":"crossref","first-page":"iv44","DOI":"10.1093\/annonc\/mdi907","article-title":"Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies","volume":"16","author":"Russo","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0145","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0150","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/ijc.23388","article-title":"Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers","volume":"122","author":"Barault","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.4001","article-title":"Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60\/00 trial)","volume":"27","author":"Tejpar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0165","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0175","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.2008.18.2071","article-title":"Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803","volume":"27","author":"Bertagnolli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0180","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.42.2592","article-title":"Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab","author":"Tejpar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0190","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","article-title":"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab","volume":"304","author":"De Roock","year":"2010","journal-title":"Jama"},{"key":"10.1093\/annonc\/mds236_bb0195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0959-8049(11)70132-0","article-title":"Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)","volume":"47","author":"Peeters","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0200","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3523","article-title":"Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC)","volume":"29","author":"Seymour","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0210","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0215","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0220","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2010.34.5520","article-title":"Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer","volume":"29","author":"Price","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.2008-0213","article-title":"The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer","volume":"14","author":"Hurwitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds236_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3531","article-title":"Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study","volume":"29","author":"Weickhardt","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0240","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2011.85","article-title":"Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer","volume":"104","author":"Loupakis","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0245","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","article-title":"Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial","volume":"26","author":"Braun","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0250","first-page":"321","volume":"7","author":"Koopman","year":"2009"},{"key":"10.1093\/annonc\/mds236_bb0255","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ejca.2009.04.017","article-title":"Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study","volume":"45","author":"Koopman","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0260","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","article-title":"Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05","volume":"28","author":"Boige","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0265","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2010.34.4473","article-title":"Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer","volume":"29","author":"Glimelius","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0270","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1148\/radiol.2323031368","article-title":"Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging\u2013a meta-analysis","volume":"232","author":"Bipat","year":"2004","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mds236_bb0275","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1148\/radiol.2532090027","article-title":"Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy","volume":"253","author":"Kim","year":"2009","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mds236_bb0280","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1245\/s10434-011-1607-5","article-title":"Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study","volume":"18","author":"Lambregts","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mds236_bb0285","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1148\/radiol.11102467","article-title":"Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy\u2013conventional MR volumetry versus diffusion-weighted MR imaging","volume":"260","author":"Curvo-Semedo","year":"2011","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mds236_bb0290","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2010.12.002","article-title":"Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging","volume":"98","author":"van Stiphout","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mds236_bb0295","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1200\/JCO.2005.02.9231","article-title":"Low rectal cancer: a call for a change of approach in abdominoperineal resection","volume":"23","author":"Nagtegaal","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2011.157","article-title":"Has the new TNM classification for colorectal cancer improved care?","volume":"9","author":"Nagtegaal","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0310","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3503","article-title":"The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04","volume":"29","author":"Roh","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0315","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"Gerard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0320","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0325","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","article-title":"Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial","volume":"13","author":"Rodel","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3506","article-title":"An analysis of preoperative chemoradiotherapy with 5FU\/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?","volume":"29","author":"Bonnetain","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0335","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/ijc.24247","article-title":"Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis","volume":"124","author":"Ceelen","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0340","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","article-title":"Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials","volume":"29","author":"Valentini","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0345","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0350","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1200\/JCO.2009.22.0467","article-title":"Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03","volume":"27","author":"Roh","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF02049863","article-title":"Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects","volume":"36","author":"Frykholm","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"10.1093\/annonc\/mds236_bb0360","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.25.8541","volume":"28","author":"Fernandez-Martos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0365","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2005.04.4875","article-title":"Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer","volume":"24","author":"Chau","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0370","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3637","article-title":"Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study","volume":"28","author":"Mar\u00e9chal","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0375","volume":"29","author":"Dewdney","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0380","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3511","article-title":"Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer","volume":"28","author":"Schrag","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0385","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0390","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.3527","article-title":"Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GRECCAR 1","volume":"24","author":"Rouanet","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0395","first-page":"1465","article-title":"Gastrointestinal Tumor Study Group","volume":"312","author":"Prolongation of the disease-free interval in surgically treated rectal carcinoma","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0400","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199408253310803","article-title":"Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery","volume":"331","author":"O'Connell","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0405","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2010.07.012","article-title":"Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mds236_bb0410","first-page":"1130","article-title":"Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group","volume":"84","author":"Tveit","year":"1997","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mds236_bb0415","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199103143241101","article-title":"Effective surgical adjuvant therapy for high-risk rectal carcinoma","volume":"324","author":"Krook","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0420","first-page":"213","article-title":"[Combination of surgery, radiotherapy and chemotherapy for rectal cancer\u2013a 423 cases report]","volume":"14","author":"Li","year":"1992","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1093\/annonc\/mds236_bb0425","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0430","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","author":"Gray","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0435","first-page":"S113","article-title":"Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer","volume":"96","author":"Cionini L","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mds236_bb0440","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(08)60651-0","article-title":"Adjuvant chemotherapy for rectal cancer: authors' reply","volume":"371","author":"Gray","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0445","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1200\/JCO.2007.11.9685","volume":"25","author":"Collette","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0450","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/annonc\/mdq054","article-title":"Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials","volume":"21","author":"Bujko","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0455","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/annonc\/mdq263","article-title":"Adjuvant chemotherapy in rectal cancer\u2013an issue or a nonissue?","volume":"21","author":"Glimelius","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0460","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0465","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3568","article-title":"FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report","volume":"29","author":"Morton","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0470","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10350-008-9246-z","article-title":"Identification of patients with high-risk stage II colon cancer for adjuvant therapy","volume":"51","author":"Quah","year":"2008","journal-title":"Dis Colon Rectum"},{"key":"10.1093\/annonc\/mds236_bb0475","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/djk092","article-title":"Lymph node evaluation and survival after curative resection of colon cancer: systematic review","volume":"99","author":"Chang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds236_bb0480","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3524","article-title":"Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors","volume":"28","author":"Teixeira","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0485","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3507","article-title":"The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil\/leucovorin (FU\/L) in stage II colon cancer","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0490","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0495","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0500","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andre","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0505","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0510","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0515","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2005.04.7498","article-title":"Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06","volume":"24","author":"Lembersky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0520","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0525","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.4010","article-title":"Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II\/III colon cancer: Findings from the ACCENT Database","volume":"27","author":"Jackson McCleary","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0530","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3521","article-title":"Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU\/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS)","volume":"28","author":"Haller","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0535","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jnci\/djr524","article-title":"Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"104","author":"Sanoff","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds236_bb0540","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","article-title":"Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0545","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/annonc\/mdi116","article-title":"A randomised comparison between 6 months of bolus fluorouracil\/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer","volume":"16","author":"Chau","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0550","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdm582","article-title":"Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?","volume":"19","author":"Berglund","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0555","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1002\/cncr.22316","article-title":"Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer","volume":"107","author":"Hershman","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds236_bb0560","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"Jama"},{"key":"10.1093\/annonc\/mds236_bb0565","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2003.10.065","article-title":"Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial","volume":"21","author":"Andre","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0570","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2008.20.9817","article-title":"Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment","volume":"27","author":"Poultsides","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0575","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3527","article-title":"A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10","volume":"28","author":"McCahill","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0580","first-page":"643","article-title":"Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol","volume":"7","author":"Weber","year":"2000"},{"key":"10.1093\/annonc\/mds236_bb0585","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds236_bb0590","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0595","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3519","article-title":"Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases","volume":"29","author":"Adam","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0600","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0605","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0610","article-title":"Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC\/NCIC CTG\/GIVIO) randomized trial","volume":"21","author":"Langer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0615","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/annonc\/mdp236","article-title":"A randomized phase III study comparing adjuvant 5-fluorouracil\/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0620","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","article-title":"Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer","volume":"341","author":"Kemeny","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0625","first-page":"1499","article-title":"Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy\u2013an intergroup study","volume":"20","author":"Kemeny","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0630","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3565","article-title":"A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer","volume":"29","author":"Voest","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0635","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000323820","article-title":"Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?","volume":"28","author":"Gaujoux","year":"2011","journal-title":"Dig Surg"},{"key":"10.1093\/annonc\/mds236_bb0640","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2006.05.8727","article-title":"Complete response of colorectal liver metastases after chemotherapy: does it mean cure?","volume":"24","author":"Benoist","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0645","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds236_bb0650","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.surg.2009.02.004","article-title":"Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases","volume":"146","author":"Neumann","year":"2009","journal-title":"Surgery"},{"key":"10.1093\/annonc\/mds236_bb0655","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/SLA.0b013e31818a07f1","article-title":"R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?","volume":"248","author":"de Haas","year":"2008","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds236_bb0660","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1200\/JCO.2004.00.6155","article-title":"Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?","volume":"23","author":"Khatri","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0665","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdq385","article-title":"Phase II study of helical tomotherapy for oligometastatic colorectal cancer","volume":"22","author":"Engels","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0670","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2009.23.4450","article-title":"2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0675","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0680","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.athoracsur.2004.02.017","article-title":"Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma","volume":"78","author":"Inoue","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1093\/annonc\/mds236_bb0685","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2008.17.7931","article-title":"Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials","volume":"27","author":"Kabbinavar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0690","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2008.20.2879","article-title":"Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0695","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2007.14.0509","article-title":"Irinotecan\/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials","volume":"26","author":"Folprecht","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0700","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0705","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2008.16.7759","article-title":"Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials","volume":"26","author":"Arkenau","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0710","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","volume":"19","author":"Rothenberg","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0715","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group","volume":"25","author":"Porschen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0720","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"Diaz-Rubio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0725","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0730","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"Kohne","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0735","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0740","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CCC.2004.n.009","article-title":"Phase II trial of capecitabine\/irinotecan and capecitabine\/oxaliplatin in advanced gastrointestinal cancers","volume":"4","author":"Jordan","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mds236_bb0745","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0750","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4030","article-title":"Activity of the combination of bevacizumab (Bev) with capecitabine\/irinotecan (CapIri\/Bev) or capecitabine\/oxaliplatin (CapOx\/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)","volume":"26","author":"Reinacher-Schick","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0755","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.4086","article-title":"Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV+FOLFIRI versus BEV+XELIRI (FNCLCC ACCORD 13\/0503 study)","volume":"27","author":"Ducreux","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0760","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0765","first-page":"1635","article-title":"Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study","volume":"23","author":"Morelli","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mds236_bb0770","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0775","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0780","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-007-0588-3","article-title":"Tritherapy with fluorouracil\/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases","volume":"62","author":"Ychou","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mds236_bb0785","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/annonc\/mdm347","article-title":"Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I\/II study in first-line treatment of metastatic colorectal cancer","volume":"18","author":"Bajetta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0790","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/sj.bjc.6605075","article-title":"A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer","volume":"100","author":"Vasile","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0795","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bjc.6605595","article-title":"Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis","volume":"102","author":"Zarate","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0800","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000313598","article-title":"Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced\/metastatic colorectal cancer: a phase I trial (SAKK 41\/03)","volume":"33","author":"von Moos","year":"2010","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mds236_bb0805","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0810","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0815","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0820","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0825","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0830","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0835","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0840","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3510","article-title":"Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first 2011 line metastatic colorectal cancer (mCRC)","volume":"29","author":"Douillard","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0845","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0850","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3506","article-title":"Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status","volume":"28","author":"Bokemeyer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0855","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0860","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0865","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3576","article-title":"Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies","volume":"29","author":"Kohne","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0870","article-title":"Randomized Phase III study of 5-Fluorouracil\/folinate\/oxaliplatin given continously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314)","volume":"21","author":"Tveit","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0875","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0880","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb0885","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0890","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds236_bb0895","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mds236_bb0900","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1093\/annonc\/mds236_bb0905","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1751-2980.2009.00393.x","article-title":"Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer","volume":"10","author":"Nie","year":"2009","journal-title":"J Dig Dis"},{"key":"10.1093\/annonc\/mds236_bb0910","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2013an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mds236_bb0915","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0920","doi-asserted-by":"crossref","first-page":"O","DOI":"10.1016\/S0923-7534(19)66488-4","article-title":"Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM)","volume":"23","author":"Pericay","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0925","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.40.4194","volume":"30","author":"Grothey","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0930","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0959-8049(11)70113-7","article-title":"A Phase I\/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer","volume":"47","author":"Van Cutsem","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb0935","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.42.5355","article-title":"Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)","author":"Schmoll","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0940","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1200\/JCO.2005.07.740","article-title":"Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study","volume":"23","author":"Alberts","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0945","article-title":"Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT-11\/L-OHP\/LV5FU (Folfirinox): A prospective phase II trial","volume":"23","author":"Quenet F","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0950","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0955","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e15020","article-title":"POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11\/5-fluorouracil (5-FU)\/leucovorin(FA)\/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM)","volume":"27","author":"Garufi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0960","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds236_bb0965","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/1471-2407-10-567","article-title":"\"Poker\" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B\/FOx) in first line treatment of metastatic colorectal cancer: a phase II study","volume":"10","author":"Bruera","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mds236_bb0970","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/annonc\/mdq714","article-title":"A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection","volume":"22","author":"Wong","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0975","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4022","article-title":"Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT)+bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0980","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1200\/JCO.2005.04.4792","article-title":"Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line","volume":"23","author":"Grothey","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb0985","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb0990","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/annonc\/mdn638","article-title":"Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer","volume":"20","author":"Cunningham","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb0995","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/sj.bjc.6602841","article-title":"A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer","volume":"93","author":"Ackland","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds236_bb1000","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.1992.10.6.904","article-title":"Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial","volume":"10","author":"Nordic Gastrointestinal Tumor Adjuvant Therapy Group","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds236_bb1015","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1245\/s10434-009-0492-7","article-title":"The role of preoperative chemotherapy in patients with resectable colorectal liver metastases","volume":"16","author":"Benoist","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mds236_bb1020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb1025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2013a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1030","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1035","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/annonc\/mdq580","article-title":"Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial","volume":"22","author":"Labianca","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb1040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","article-title":"Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial","volume":"361","author":"Maughan","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb1045","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4010","article-title":"Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study","volume":"17","author":"Diaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds236_bb1055","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.4_suppl.536","article-title":"Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-b trial","volume":"30","author":"Wasan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1060","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mds236_bb1065","doi-asserted-by":"crossref","first-page":"CRA3503","DOI":"10.1200\/jco.2012.30.15_suppl.cra3503","article-title":"Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study)","volume":"30","author":"Arnold","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1080","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1085","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds236_bb1095","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1100","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","article-title":"Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study","volume":"26","author":"Wilke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1105","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mds236_bb1110","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb1115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mds236_bb1120","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","article-title":"Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5","volume":"28","author":"Wolf","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1125","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","article-title":"The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study","volume":"137","author":"Zhang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1135","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","article-title":"Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion","volume":"22","author":"Potthoff","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb1145","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1150","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005228.pub3","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","volume":"2","author":"Albers","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mds236_bb1155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1160","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds236_bb1170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mds236_bb1175","doi-asserted-by":"crossref","first-page":"v70","DOI":"10.1093\/annonc\/mdq168","article-title":"Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up","volume":"21","author":"Labianca","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds236_bb1180","first-page":"843","article-title":"Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases","volume":"106","author":"Schmiegel","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"10.1093\/annonc\/mds236_bb1185","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2005.04.0063","article-title":"Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline","volume":"23","author":"Desch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1190","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","article-title":"Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer","volume":"26","author":"Braendengen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1195","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.3522","article-title":"Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials","volume":"30","author":"Haller","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2004.01.004","article-title":"Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer","volume":"70","author":"Bystrom","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mds236_bb1205","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/00001813-200211000-00004","article-title":"Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer","volume":"13","author":"Schiebe","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mds236_bb1210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3512","article-title":"The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: Preliminary results of a phase III trial","volume":"29","author":"Jakobsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds236_bb1215","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/02841860701798866","article-title":"Long-term results of a phase II trial of high-dose radiotherapy (60\u00a0Gy) and UFT\/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)","volume":"47","author":"Vestermark","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mds236_bb1220","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(11)60654-5","article-title":"Do we need oncology trials tailored for the elderly or frail?","volume":"377","author":"Schmoll","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds236_bb1225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(07)61062-9","article-title":"Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?","volume":"370","author":"Schmoll","year":"2007","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/10\/2479\/488404\/mds236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:28:05Z","timestamp":1624519685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":244,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0923753419379803"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds236","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}